The guidelines of NAFLD recommend the FIB-4 index or NAFLD fibrosis score, both of which comprise serum ALT levels, to stratify the risk of advanced fibrosis and avoid unnecessary liver biopsy10,11. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.